ANGPTL6 and hepatocellular carcinoma: Strengths of this study: First, by ELISA of serum ANGPTL6 levels in HBV-related early primary HCC patients with normal serum AFP levels and in the noncancer group, we identified ANGPTL6 as a potential biomarker to compensate for the lack of ability of serum AFP to diagnose early HCC.